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Mutations  in  the H-2 complex  in  the  mouse  have  proven  to  be  of considerable 
interest and have led to a clearer conceptual definition of the murine major histocom- 
patibility complex  (MHC) a  (1,  2).  Thus  far  there  have  been  24  spontaneous  H-2 
mutations described, and one which may have been chemically induced (1, 2). These 
mutations have been detected by the rejection of parental skin grafts and thus may be 
recorded as a gain, loss or both a gain and loss mutation (1, 2). All of the H-2 mutants 
described  thus  far  have  been  found  by  the  gene-complementation  and  other,  less 
direct  methods,  to  involve the H-2K or H-2D loci of the b,  d, f,  and  k  haplotypes, 
although  H-2K  b is  the  most  common  site of mutation,  as  14  H-2K  b mutants  have 
already been described (1, 2). Another mutant, BALB/e-H-2 am2, is of interest in that 
it is a  loss mutation involving the H-2L  a locus (3). Studies of these H-2 mutants have 
revealed: (a) extensive T-cell-mediated effects can be produced by alteration of H-2D 
or H-2K molecules without  accompanying serologically detected changes  (1-5);  (b) 
the T-cell effects are a  result of the presence of multiple specificities, possibly in the 
order of 19 or more (5, 6);  and  (c) the presence of the H-2L locus--already described 
by extensive serological testing (7). The mutants have also been of value in defining 
the relationship of the T-cell specificities detected in cell-mediated lympholysis (CML) 
assays  involving  H-2K,  D,  and  L  target  ceils  bearing  these  antigens  in  normal, 
trinitrophenyl-modified and  in  virus-infected  cells  (8-10).  The  H-2  mutants  have 
clearly given a new dimension in studies of the murine MHC, particularly with regard 
to phenomenon  associated with  H-2K,  H-2D,  and  H-2L.  We now  describe another 
spontaneous mutation in the H-2 complex of C57BL/6.  The mutation is of the gain 
and loss type as defined by skin graft-rejection patterns.  However, in contrast to the 
H-2K  b mutants  of C57BL/6,  this new  mutation appears to have occurred  in  the IA 
subregion, z 
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2 The bm  TM mutant was shown in early tests to have an apparent alteration of the H-2.33 specificity 
detected by the serum (B10.A × A)F~ anti-B10.A(5R). It was assumed therefore to be a new mutation in 
the K region and was verbally reported as such by I. McKenzie in meetings at Wood's Hole, Mass., 1978 
and London,  1979. This assumption was incorrect as shown by the data presented herein. 
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Materials  and  Methods 
Mice.  The mice used are listed in the Tables. 3 The inbred strains were maintained by strict 
brother X sister breeding in Melbourne, Australia. The mutant, produced as C57BL/6-H-2 bin12 
(henceforth referred to as bm x2) was freighted to Melbourne from the Harvard Medical School 
and  Warren  Radiation  Center,  New  England  Deaconess  Hospital,  Boston,  Mass.  The  bm 12 
mutant  arose in a  (C57BL/6Kh  ×  BALB/cKh)F1 and the mutation was shown to be in the H- 
2 b haplotype of C57BL/6. The original Fa hybrid mouse bearing the mutation was backcrossed 
and made congenic with C57BL/6Kh  (12). 
Serological Studies.  Antisera  were  produced  as  previously described  (3).  Some  H-2  and  Ia 
antisera were obtained from Dr. J. Ray of the Transplantation  Immunology Branch, National 
Institute of Allergy and Infectious Diseases, Bethesda,  Md. and are described in the Institute's 
Catalog of Mouse Alloantisera.  Cytotoxicity, and  absorption  testing using cytotoxicity, were 
performed as previously described (5).  For these tests, selected rabbit sera were used as a source 
of complement.  Rosetting assays  for direct testing and absorption  were also performed,  using 
sheep  anti-mouse  IgG coupled  to sheep  erythrocytes with chromic chloride  (11).  The spleen 
cells had their surface Ig removed by capping before use (11). All sera used and their cytotoxicity 
and rosetting titers are shown in the Tables. Erythrocytes were also tested by the hemaggluti- 
nation method (3, 5). 
Skin Grafting and Complementation Studies.  Skin grafts were performed as described elsewhere 
(3,  11) using either tail skin to dorsum  (Melbourne) or tail skin to tail (Boston). To genetically 
map the site of the mutation, the standard gene-complementation test was performed (2). This 
involved grafting C57BL/6Kh skin to F1 recipients formed by mating a C57BL/10 recombinant 
strain  (differing  from  the  H-2  b  haplotype  at  known  loci)  with  the  bm 12  mutant.  In  these 
circumstances,  graft rejection indicates a  failure of the recombinant strain to complement the 
bm 12 mutant  for a  C57BL/6 graft,  and so the recombinant  and  mutant  strain  both  lack the 
necessary H-2  b gene required for complementation. Graft acceptance indicates that  the recom- 
binant strain carries the appropriate H-2  b gene so that  (recombinant  ×  bm12)Fi  is identical to 
the parental  C57BL/6 strain. 
Mixed Lymphocyte Reaction (MLR) 
CELL  PREI~ARATXON.  Spleen  and  lymph  node  cells  were  teased  in  RPMI-1640  medium 
(Commonwealth Serum Laboratories,  Melbourne, Australia)  supplemented  with 2.5% human 
serum, 20 mM Hepes buffer,  100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM/L-glutamine 
and 5 ×  10  -~ M  2-mercaptoethanol.  Cell suspensions were centrifuged at  1,000 rpm  for 5 rain 
and washed twice. 
CULTURE CONDmONS.  Responder lymph node cells were adjusted  to  1 X  10  6 viable cells/ 
ml. Spleen cells at 5 ×  106/ml were treated with mitomycin C  (Sigma Chemical Co., St. Louis, 
Mo.)  at 25/~g/ml for 25 min at  37°C, washed three times and finally adjusted  to 2  ×  106/ml 
and used as stimulating cells in the MLR. Responder cells (0.1  ml) were cultured with 0.1  ml 
of stimulator cells in U-bottom Cooke microtiter plates  (Cooke Engineering Co., Alexandria, 
Va.). Cultures were set up in quadruplicate incubated at 37°C in a  humidified atmosphere of 
10%  CO2/90%  air for 4  d,  labeled  with  [aH]thymidine  (2/zCi/well;  5  Ci/mmol sp  act)  and 
incubated for a  further 20-24 h. Cells were harvested, using a  Skatron  multiple cell harvester 
(Flow Laboratories,  Sydney, Australia)  on to glass fiber filters (Titertek filter mats, catalogue 
No.  77-300-06,  Flow Laboratories)  which were then dried and placed into vials containing  10 
ml of scintillation fluid  [1.1  g  POPOP,  (Kochlight  Laboratories,  Buckinghamshire,  England) 
5 g PPO (Packard,  Melbourne, Australia)  per I of toluene]. 
Results 
Description ofbm 12 Mutant.  The  bm lz mutant  was  first  detected  as  a  gain  and  loss 
mutation  in  grafting  between  (C57BL/6  ×  BALB/c)F1  mice.  The  mutation  was 
3 The most recent listing of all available mutants, their haplotypes, properties  and origin will be found 
in (a) Kohn, H. I.,J. Klein, R. W. Melvold, S. G. Nathenson, D. Pious, and D. C. Shreffler.  1978. The first 
H-2 mutant workshop.  Immunogenetics. 8:279 and  (b) Melvold, R. W.  1979. Mutant H-2 haplotypes of the 
H-2 gene complex. In FASEB Handbook of Inbred and Genetically Defined Strains of Laboratory Animals. 
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TABLE  I 
Graft Rejection Studies in the bm  t~ H-2 Mutant Strain * 
Median survival 
Donor  Recipient  time  Conclusion 
d  "t-  SD 
C57BL/6Kh  bm  lz  16.2 +  2.8  Loss mutation in bm  12 
C57BL/6  (bin  12 X LP.RIII)FI  12.2 _  1.2  Loss mutation in bm  12 
C57BL/6  bm  12 (immune)~  7.2 ziz  1.4  Loss mutation in bm  12 
bm  12  C57BL/6  14.8 -1- 2.1  Gain mutation in bm  12 
* Groups of 6-10 female mice grafted with tail skin from donors of the same sex. 
:~ Mice immunized by a preceding skin graft. 
shown to be in the H-2  b haplotype of C57BL/6  (see below)  and the strain was then 
made  homozygous on  a  C57BL/6Kh  background.  Both  C57BL/6  and  bm a2 reject 
each other's skin grafts in  14-16 d  (Table I) indicating that the mutation is of both 
the gain and loss type, and further,  the mutation has induced  histogenic changes of 
similar strength to the strongest responses found with the H-2K b mutants (4). 
Mapping the bm tx Mutation to the IA subregion  of C57BL/6.  The results of the original 
studies (12)  and of the complementation studies indicate several points of importance 
(Table II). Firstly, the finding that the (B6.C-H-2  d X bm12)F1 hybrid rejects C57BL/ 
6 grafts indicates that the mutation is not in the H-2  d haplotype of BALB/c but has 
occurred  in  the  H-2  b  haplotype,  particularly  as  the  original  Fa  mutant  rejected 
C57BL/6  and  accepted BALB/c grafts.  Secondly, crosses with  other  H-2  b mutants 
indicate  that  the  bm 12  mutant  occurred  at  a  third  mutational  site within  the  H-2  b 
haplotype. This was shown by the cross with bm  13 which we have mapped to H-2D b 
(G.  M.  Morgan,  H.  Dellos,  I. F.  C.  McKenzie,  D.  W.  Bailey, and  R.  W.  Melvold. 
Studies of the bm  la and bm 14 mutants of C57BL/6.  Manuscript in preparation.). The 
ability  of bm  13  to complement  the  bm  12  mutant  indicates  that  the  bm  12  mutation 
occurred at a site other than H-2D b locus. Crosses with four different H-2K  b mutants 
(bm  1, bm  5, bm  6, and bmS), which are all mutant alleles at the one (H-2K  b) mutational 
locus, also complemented the mutant bm  lz strain for a C57BL/6 graft. These results 
demonstrate that this second mutational site, probably H-2K  b itself, is also not the site 
of the bm a2 mutation, which must therefore have occurred at a third H-2  b mutational 
site,  distinct  from both  H-2K  b and  H-2D b.  Complementation occurred  in  the  cross 
with  B10.A(5R)  which  localized  the  mutation  either  to  K b,  IA b or,  IB  b subregion. 
Finally,  complementation  studies  in  two  other  crosses  with  B10.A(4R)  or  D2.GD 
excluded the IB  b subregion. The bm 12 mutation therefore occurred in either the IA ~ 
subregion or in the H-2K  b region, but at a different site to the H-2K  b locus. (This was 
our  first,  but  incorrect  conclusion. 2)  However,  from  the  serological  evidence  it  is 
extremely likely that the mutation occurred in the IA subregion. 
Serological Studies Comparing C57BL/6 and bm le with H-2 Alloantisera.  The sera used 
and the results obtained are shown in Table III. When tested directly using cytotox- 
icity with rabbit serum as a source of complement, all sera, with the exception of an 
H-2.33  antiserum  gave identical  or  similar  results  with  the  C57BL/6Kh  parental 
strain and  the  bm 12  mutant, i.e., there was no difference in  the reaction of the two 
strains with sera detecting the H-2.2, 5, 27, 28, 29, 35, and 36 specificities (Table III). 
With  the  H-2.33  antisera,  several different  patterns of reaction  were observed with 
the two different antisera (Table III and Fig.  1). The D33 and AS924 sera both gave 1326  bml~: AN I  REGION  MUTANT 
TABLE II 
Complementation Studies to Map the Site of the bm t2 Mutation 
Strains  H-2 haplotype 
crossed with  Rejee-  Comple- 
bm  TM to make  tion of  ments 
F1 hybrid re-  parental  (C) or 
cipientsfor  K  IA  IB  IJ  IE  IC  S  G  D  C57BL/  not 
C57BL/6  6 graft  (NC) 
skin grafts* 
Conclusion 
B6.C-H-2  a  d  d  d  d  d  d  d  d  d  yes  NC  Mutation not in H-2 a 
C57BL/6  b  b  b  b  b  b  b  b  b  no  --  Control 
bm  13  b  b  b  b  b  b  b  b  b:~  no  C  Mutation not in H-2D b 
bm l,bm  8,bm  ~,  b~  b  b  b  b  b  b  b  b  no  C  Mutation not in samelo- 
bm  6  cus as H-2K b mutants, 
therefore probably not 
in H-2K b 
B10.A(5R)  b  b  b  k  k  d  d  d  d  no  C  Mutation in K b, 1A b, IB b 
B10.A(4R)  k  k  b  b  b  b  b  b  b  yes  NC  Mutation in K h or IAb 
D2.GD  d  d  b  b  b  b  b  b  b  yes  NC  Mutation in K  b or IA b 
* The strains listed in the column were crossed with bm 12 and the FI hybrid grafted with C57BL/6Kh skin 
from a donor of the same sex. Groups of 6-I0 mice were used. Grafts either did not reject in periods of 
observation >60 d or were rejected in 12-18 d. 
Mutational site. 
similar direct reaction patterns and titers. These two sera, made as  (B10.D2 ×  A)F1 
anti-B10.A(5R) could  potentially contain anti-Ia.9 and  20  antibodies. The  titer of 
bm  TM  with these sera was  lower than found in C57BL/6 although the shape of the 
titration curve did not differ in the two strains. Furthermore, AS924 absorbed with 
A.TH, to remove the Ia.9 antibody, gave similar titers on both C57BL/6 and bm 12. 
Clearly the  H-2.33  specificity is  represented equally on both strains.  However two 
other sera, AS 1117 and a  similar serum (kindly provided by Dr. C.  S.  David, Mayo 
Clinic,  Rochester,  Minn.)  and  made  as  (B10.A  ×  A)F1  anti-B10.A(5R)  gave  a 
different  reaction  (Fig.  1).  These sera could and do contain anti-Ia antibodies. On 
testing the parental C57BL/6 strain, there were two plateaus of reaction: (a)  >90% 
lysis indicative of lysis resulting from H-2.38 antibodies, and (b)  ~60% lysis, presum- 
ably a  result of the Ia antibodies. When these sera were tested on the bm  12 mutant, 
only one plateau with >90% lysis was observed and the second Ia plateau was absent 
(Fig.  1). This finding suggested that the bm  12 mutant was not reacting with the anti- 
Ia  component  in  these  sera  and  therefore  might  have  altered  Ia  specificities,  the 
alteration being produced  by the  mutation. Further studies with  the  H-2  antisera 
involved  testing  by  absorption  using  the  same  sera.  Except  for  the  H-2.33  sera, 
identical absorption patterns were obtained with all the H-2 antisera. Two of these 
are shown in Fig. 2 a, b; H-2.5, a  public H-2 b specificity, and the serum D28 contains 
antibodies to the H-2.28 family of specificities. There is obviously no difference in the 
absorption capacity of either strain for serum D28  (Fig. 2 a)  or for D5  (Fig. 2 b)  and 
identical absorption of C57BL/6 and bm  12 were apparent for the other H-2 specificities 
(data  not  shown).  By  contrast,  the  two  different  anti-H-2.33  sera  gave  different 
absorption patterns  (Fig.  3a,  b).  One serum,  AS924,  demonstrated  that  bm  lz  had 
slightly less absorptive capacity when compared with C57BL/6 (Fig. 3 a). The other 
serum (from C.  S.  David)  gave very different results in that C57BL/6 could absorb McKENZIE,  MORGAN,  SANDRIN,  MICHAELIDES,  MELVOLD,  AND  KOHN 
TABLE III 
Comparison of C57BL/Kh and bm 12 Using H-2 Alloantisera 
1327 
Specificity 
Other specifici-  Cytotoxic titer on 
ties potentially  Donor  Recipient  spleen cells 
H-2K/D  Antiserum No.  reactive  with 
tt-2 b  C57BL/6"  bm 12 
Public 
H-2.5 
H-2.27, 28, 29 
H-2.35  K 
H-2.36  K 
Private 
H-2.2  D 
H-2.33  K 
K 
K/D 
D5  --  BI0.PL(73NS)  (BIO.M  x  DBA/2)F~  1/32  1/64 
AS235  --  BIO.PL(73NS) (BI0.M X DBA/2)F~  1132  1/64 
D28  Ia.9, H-2.36  A.SW  (A.CA x  BIO.BR)FI  1/128  1/128 
AS274  [a.9, H-2.36  A.SW  (A.CA X BI0.BR)FI  1/128  1/128 
AS834  H-22, 56  BI0.A(2R)  (BIO.BR × LP.RII1)F~  1/256  1/256 
D28b  H-2.2, 56  BIO.A(2R)  (BIO.BR ×  I.P.RIII)Ft  1/64  1/64 
D29  H-2.56  AKR.M  (SJL × AKR)F~  1/32  1/32 
AS276  H-2.56  AKR.M  (SJL × AKR)F~  1/128  1/128 
D35  --  BI0.Y  (BIO.A(2R) × A.CA)Fj  1/128  1/128 
AS190  --  BI0,Y  (BIO.A(2R) x A.CA)F~  1/64  1/64 
D36  la9  A.SW  (BlO A(2R) × A.CA)F~  118-1116  1/8-1/16 
AS946  H-2.56  BIO.A(2R)  (Blfi D2 x A)Ft  1/128  1/128 
D33  H-2.39,  53,  BIO.A(5R)  (BI0.D2 x  A)F=  1/800  1/400 
54, 62, Ia.9, 
20 
AS924  H-2.39,  53,  BI0.A(5R)  (BIO.D2 x  A)Ft  1/512  1/512 
54, 62, It.9. 
2O 
AS924 abs. A.TH  Ia.20  BIO.A(5R)  (BIO.D2 × A)F1  1/512  1/512 
C. S. David  la.8, 9, 20  BI0.A(5R)  (BIO.A × A)FI  1/128  1/128 
ASI 117  laB, 9, 20  BIO.A(5R)  (BIOA × A)F~  1/128  1/64 
* C57BL/6 has these specificities: H-2: 2, 5, 27, 28, 29, 33, 25, 26: la: 3.8, 9, 15, 20 
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FIG.  1.  Direct cytotoxicity testing on C57BL/6  (0)  and the bm 12 mutant  (X). The percentage  of 
lysis is shown and dilution  (log2). C57BL/6  gives two plateaus of reaction:  one with 90% lysis, one 
with -60%  lysis. The mutant  bm la has only the one plateau at  90%  lysis. The rabbit complement 
(RC)  control  (not shown)  was <20%  lysis. 
this  serum,  but  the  bm lz  mutant  had  little  absorptive  capacity  (Fig.  3b).  (These 
results caused us initially to consider bm 12 to be a new H-2K  b mutant. See footnote 2.) 
The  results  with  the  H-2  sera  suggest  that  all  the  H-2  specificities  (except  H-2.33) 
were identical  in the C57BL/6  and bm 12 mutant  and that  a specificity  in the H-2.33 
serum,  probably  not  H-2.33  itself,  was  lacking  in  the  bm 12  mutant.  Testing  by 
hemagglutination  revealed no differences  between C57BL/6Kh  and bm 12. 
Serological  Studies  with  Anti-Ia  Sera.  When  the  parental  C57BL/6Kh  and  bm t2 
mutant were examined with sera of the known Ia specificities  it was apparent that the 1328  bml2: AN I  REGION  MUTANT 
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Fro. 2.  Absorption  of two  H-2  antisera  with  C57BL/6  (0)  and  bm 12  (X), and  testing,  by 
cytotoxicity on C57BL/6 spleen cells showing the percentage of lysis and the number of absorbing 
cells used. (m) nonabsorbed control (NA). The RC control was <20%. (a) absorption of serum D28; 
(b) absorption of serum D5. Both strains absorb equally. 
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FIG. 3.  Absorption of two different H-2.33 antisera with C57BL/6  (0) and the bm 12 mutant (X) 
and testing back on C57BL/6 by cytotoxicity. The nonabsorbed sera (', NA) gave >90% lysis. (a) 
absorption  of AS924:(B10.D2  X A)F] anti-B10.A(5R);  (b)  absorption  of (BI0.A  x  A)F1 anti- 
B L0.A(5R). 
mutant  strain  had  a  marked  decrease or absence of the  Iab specificities (Table  IV, 
Figs. 4-8). 
Ia.3,  15.  The  serum  A.TH  anti-A.TL  (AS1070),  containing  Ia.3,  15  antibodies 
reactive  with  C57BL/6  had  a  reduced  cytotoxic  reaction  with  bm TM  (titer  1/32) 
compared  with  C57BL/6  (titer  1/256)  (Table  IV,  Fig.  4a),  but  this  was  not  so 
apparent with the more sensitive rosetting procedure (Table IV, Fig. 4 b, i.e., titers of 
1/1,500  vs.  1/3,000).  A  similar  result  was  obtained  using  AS760  (B10.HTT  X 
A.SW)Fa  anti-A.TL.  The  known  specificities  in  these  sera  were  then  examined 
individually. 
la.3.  The  Ia.3  specificity was  tested  by  absorption  using  the  A.TH  anti-A.TL 
serum with  B10.T(6R)  as the target cell (Ia.3+15-). The results are shown  in Fig. 5 
where  it  is clear that  the  mutant  strain  has  a  decreased  amount  of this  specificity 
although it still appears to be present. By comparing the number of cells required to 
absorb  an  equal  amount  of antibody,  bm ]2  carries  i/4-1/8 of the  Ia.3  antigen  that 
C57BL/6Kh  carries. 
Ia. 15.  The Ia. 15 specificity was tested directly with AS767 where the bm 12 mutant 
was nonreactive by cytotoxicity and only weakly reactive by rosetting (Table IV, Fig. 
6a).  These  reactions were  also examined  by absorption  (Fig. 6b)  and  this  demon- McKENZIE, MORGAN, SANDRIN, MICHAELIDES, MELVOLD, AND KOHN  1329 
TABLE IV 
Reactions of C56BL/6 and bm 12 Mutant with Anti-Ia Sera * 
Specificity 
Sera reacting with I b 
(la.3, 8,  19,  15, 20) 
la.3, 15 
la.8 
la.9 
Ia.20(?) 
Ia. 15 
? 
Other la specificities 
present in sera.~ 
1, 2, 7, 22 
16 
4, 5,  12 
Antiserum No.  Donor  Recipient 
Tilers 
C57BL/6  bml2 
Cvto-  Cyto-  RFC  '  .  RFC 
toxic  toxic 
~tS1070  A.TL  A.TH  1/256  1/3000  1/32  1/1500 
~.$742  BI0.D2  BI0.A ×  A)FI  1/128  1/640  0-1/4  1/32 
AS935  A.TH  (A.TL ×  AKR)F~  1/32  1/64  0  0-1/16 
ASIlI7  absorbedBI0.A(5R)  (BI0.A×A)F~  1/128  1/320  1/16  1/20 
with El4 
~.S767  A.TL  A.TH ×  BI0.RIII[71NS])F~  1/16  1/64  0  I/2 
ASI070  absorbed A.TI.  A.TH  1/64  1/640  0-1/4  1/160 
8, 9 
2,  19, 22 
la.3,  15 
la.8 
la.9 
Sera  reacting  with 
specificities  not 
usually found in I h 
la.I, 2 
la.4 
la.6 
la.7 
la. 10 
la. ll 
la. 13 
la. 17 
Ia.22 
Ia.7 
1,2,  19 
Monoclonal  antibodies 
from  G.  HS.mmerling 
Mon~zlonal  antibodies 
from  G.  H~immerling 
5,  12 
22 
5,  10,  13,  16 
16, 23 
5, 21 
1,2,6,  7, 15,  18,  19,22 
6,7 
6, 22 
with bm 12 
~$760  A.TL  BI0.H'I~x  A.SW)FI  1/32  --  1/8  -- 
1/16  --  O  -- 
1/16  --  0  -- 
NIH  A,TL  (A.BY ×  BI0,HTT)Fx  0  0  0  0 
NIH  A.TH  (A.TL ×  BI0.A(5R))FI  0  0  D  0 
AS915  absorbed  BI0.(2R)  (BI0.A(4R)  ×  129)Fi  0  0  0  0 
with CBA§ 
N1H  BI0.A(5R)  (C57BL/10  ×  HTT)F~  0  0  0  0 
ASI33  BI0.T(6R)  (C57L ×  AQR)Fj  0  0  0  0 
AS307  BI0.D2  (C57BL/6 ×  A)FI  0  0  0  0 
A,  S681  BDP  (C57BL/6  x  A)Fa  0  0  0  0 
AS538  AQR  BI0.T(6R)  0  0  0  0 
~$851  BI0.A(2R)  (BI0.A[4R I ×  129)F~  0  0  0  0 
--  B 10.A(2R)  BI0.A(4R)  0  0  D  0 
* Assignment of specificities and combinations used are according to published charts (21). 
$ All of the sera listed react  with the donor; the specificities in this column could potentially be present; not all are present; e.g., AS538 contains 
no la. 15 reactivity as C57BL/6 is negative. 
§ The Ia.6 specificity is difficult to produce and the sera usually contain only la.7, 22. This serum does contain  an la.6 antibody  for, after 
absorption with CBA, it is B 10.D2(+). 
strated  that  bm 12  carries  ~2-I/64  the  amount  of  Ia.15  carried  by  C57BL/6.  This 
specificity was also examined by using the A.TH anti-A.TL serum with D2.GD target 
cells (Ia.3-15 +) so that absorption resulting from the Ia. 15 specificity only is examined 
(Fig. 6 c). It was found that bm 12 has a very low absorptive capacity (1/~th)  compared 
with C57BL/6Kh.  The  Ia.15  specificity  is therefore  present  in very small  amounts, 
and may indeed be absent. 
Ia.8.  Testing for the Ia.8 specificity with AS742 demonstrated an extremely weak 
reaction with bm 12 by cytotoxicity (0-1/4 on different  occasions)  (Table IV, Fig.  7 a). 
In addition direct testing using a monoclonal Ia.8 antibody (Table IV), C57BL/6Kh 
was found to be reactive (titer 1/16), whereas bm 12 gave a barely detectable response 
(0--1/2  titer).  (This  antibody  was  provided  by  Dr.  G.  H/immerling,  Institute  for 
Genetics,  University of Cologne, Cologne, Federal  Republic of Germany;  full details 
of these tests will be provided  elsewhere.)  Direct  testing by rosetting indicated  that 
bm x2 gave a  greater reaction than by cytotoxicity (Fig.  7 b).  However,  when testing 
the AS742 serum on C57BL/6  after performing quantitative absorptions with bm 12 1330  bm12: AN  I  REGION  MUTANT 
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FIG. 5.  Absorption testing for Ia.3 using A.TH anti-A.TL antiserum  on B10.T(6R) target  cells, 
and testing by inhibition of RFC. C57BL/6  (0) bm 12 (x). (11) not absorbed (NA). 
and C57BL/6  (Fig. 7 c), it was clear that bm 12 carried no Ia.8 specificity, especially by 
rosetting (Fig.  7 b). The weak reaction of the serum directly on  bm ~2, which  is Ia.8- 
by absorption, indicates that  there are other antibodies in this serum,  reactive with 
the bm 12 mutant. This is considered further below and studies are currently in progress 
to define these specificities. 
Ia.9.  The Ia.9 specificity could not be detected on the bm ~2 mutant by cytotoxicity 
using AS735  (Table IV) but gave a  weak reaction by rosetting (Fig. 8 a). Absorption 
testing  indicated  that  the  bm 12  serum  carried  (1/16--1/32) the  amount  of Ia.9  as  the 
parental C57BL/6 strain (Fig. 8 b). A  monocloncal anti-Ia.9 antibody (obtained from 
Dr. G. Hiimmerling) was also nonreactive on the bm x2 mutant  (Table IV). 
Ia.20.  The Ia.20 specificity was tested for by using AS1117:  (B10.A  ×  A)F1 anti- 
B10.A(5R) absorbed with EL4 to remove H-2 antibodies. The serum could putatively 
contain antibodies to Ia.8, 9,  20;  it was nonreactive with bm 12 but still reacted with 
C57BL/6  (titer 1/64) and we therefore presume that Ia.20 is also missing but we have 
no independent proof that the Ia.20 specificity is represented in this antisera. 
The results presented in this section indicate that a dramatic alteration has occurred 
in the structure of the/A-coded Ia-bearing molecule in that  the specificities, Ia.3, 8, 
9,  15,  and  possibly 20  are  either  totally absent,  or  present  in  very  much  reduced 
amounts  in the bm lz mutant.  The loss mutation  detected by skin grafting therefore 
has a  serological counterpart  in that  there are losses of the Iab specificities. Is there 
any evidence of other losses or of new or gained specificities in the bm t2 mutant? We McKENZIE,  MORGAN,  SANDRIN,  MICHAELIDES,  MELVOLD,  AND KOHN  1331 
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FIo. 6.  Testing for the Ia.15 specificity with C57BL/6 (0) and the bm  TM mutant strain (×) using 
AS767 (Ia.15) (a, b) with C57BL/6 target cells, and ASI070 with D2.GD target cells (c). In (a), 
direct testing by rosetting is shown and in (b), testing is shown by absorption using the same assay 
system. In (c), absorption using cytotoxicity is recorded. (ll) nonabsorbed (NA) serum reaction. 
sought these answers by three different approaches.  Firstly, C57BL/6 and bm 12 were 
tested  with  a  range of antisera  detecting  known Ia specificities  of other haplotypes, 
e.g., for Ia.1, 2, 4, 6, 7,  10,  11,  13,  15,  16,  17,  18,  19, and 22. All were nonreactive on 
both C57BL/6 and the bm 12 mutant, although not all the sera used can be guaranteed 
to contain all the specificities listed.  However the mutation did not appear to give rise 
to  a  new  specificity  which  had  previously  been  described.  The  second  approach 
involved absorbing  sera with  the  bm 12 mutant  and  testing on C57BL/6.  Although 
these studies are still  in progress, it  is clear that serum  1070 (A.TH anti-A.TL)  does 
contain extra specificities, which can especially be detected by the rosetting procedure 
(Table  IV; Figs.  4a,  b).  This  was confirmed when  this  serum,  absorbed  with  bm 12, 
still gave a substantial reaction on C57BL/6 (Table IV). The third approach involved 
immunization.  In several  different combinations extensive immunizations  were per- 
formed but no anti-Ia antibody resulted  (Table V). This result is not too surprising as 
it  has  proven  difficult  to  produce  antisera  by  immunizing  between  mutant  and 
parental strains  (5). 1332  bml2:  AN  I  REGION  MUTANT 
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The bm 12 Mutant has Normal B-Cell Numbers.  As Ia specificities were detected only 
with  difficulty in  the  bm 12  mutant,  it  could  be considered  that  this  mouse  (which 
survives as a healthy strain but which breeds poorly) had low numbers of B cells--the 
cell  bearing  Ia  specificities  in  mouse  spleen.  Several  spleen  cell  suspensions  were 
examined  for  the  proportion  of Ig  +  rosette-forming cells  (RFC)  using  sheep  anti- 
mouse Ig coupled  to sheep erythrocytes. The results  (percentage of Ig  + cells)  were: 
C57BL/6  (52-58%);  bm 12 (51-56%);  i.e., the bm 12 mutant has a normal content of B 
cells in the spleen. 
MLR Studies  with  C57BL/6 and bm 12.  The MLR data is shown in Table VI. The 
mutation in  bm 12  has not only led to histocompatibility and serological changes in 
the  IA  subregion,  but  also  to  an  alteration  that  leads  to  a  reaction  in  the  mixed 
lymphocyte culture.  Firstly, bm 12 spleen cells are able to stimulate C57BL/6  lymph 
node cells (experiment  1, Table VI), the degree of stimulation being similar to those 
obtained  when  either  C57BL/6  (experiment  7)  or  bm 12  (experiment  8)  stimulate McKENZIE,  MORGAN,  SANDRIN,  MICHAELIDES,  MELVOLD,  AND  KOHN  1333 
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B10.A(4R)  or when  B10.A(4R)  stimulates  C57BL/6  (experiment 5).  In  the experi- 
ments  involving B10.A(4R),  there  is  a  strong  degree of stimulation  as  a  result  of 
lymphocyte-activating determinants (Lad) loci present in both the K and IA subregion 
so that the stimulation of C57BL/6 produced by bm 12 (experiment 1) is as great, or 
greater than that produced by a K  +  IA region difference. In experiment 1, C57BL/ 
6 is presumably responding to the gained specificities on bm ~2, as bm  TM is both a gain 
and loss mutation (Table I). In the reciprocal experiment (experiment 3, Table VI), 
bm  TM is able to respond to C57BL/6, although in this study, not as strongly as does 
C57BL/6 to bm  12. The presumption in this experiment is that bm  12 has lost specific- 
ities, which  are  present  in  the  parent  C57BL/6  and  which  lead  to  stimulation.  It 
should be noted that B 10.A(4R) both stimulates, and responds to C57BL/6 and bm 12 
in a similar manner (experiments 5-8). It is clear that the one mutational event has 
simultaneously effected the MLR (Lad loci) as much as the other parameters discussed 
above. 
Discussion 
The experiments reported here described the bm ~2 mutant--a spontaneous mutant 
occurring within the H-2  b complex of strain C57BL/6Kh. The mutation is of the gain 
and loss type--defined by skin grafting in that bm lz rejects parental C57BL/6 grafts 
(loss mutation) and C57BL/6 rejects bm 12 skin grafts (gain mutation). The mutation 
presumably a single gene mutation,  4 has been mapped by the standard complemen- 
tation  method  to  the  K b or  IA b  regions  of the  H-2  complex  (Table  I).  Further 
complementation studies with a series ofH-2K  b mutants (Table I) have demonstrated 
that the mutation is not in the H-2K  b locus itself, but does not exclude the mutational 
site being adjacent in the K region. Only studies with newer recombinant strains will 
solve this question. However, the mapping by complementation also includes the IA 
subregion and in this subregion is another histocompatibility locus, H-2IA, and it is 
entirely possible that the bm x2 mutation has effected this gene, particularly as there 
is also clear evidence for an alteration in the Ia specificities which are coded for by 
genes  in  the  IA  subregion.  Taken  together,  the  complementation  and  serological 
4 Whether bm  TM has a point mutation is not clear at present. Most of the H-2K b mutants appear to have 
single amino acid substitutions in their sequence indicating they probably arose as a  point mutation (2, 
13). By contrast, another mutant--H-2  a"t appears to have a frame shift or other type of mutation as there 
is an alteration in the D a and L d molecules revealed both serologically and by amino acid sequence studies 
(14,  15). Whether bm  12  is a  point  mutation or involves a  more extensive gene alteration  awaits further 
serological study and amino acid analysis. 1334  bm12:  AN  1  REGION  MUTANT 
TABLE  V 
Attempts to Produce Antisera by Immunizing Between Parental C57BL/6 and the 
bm 12 Mutant 
Antiserum  Donor  Recipient 
No. 
Titers* 
Cyto-  Roset- 
toxic  ting 
--  bm  12  C57BL/6  0  0 
AS1150  bm  TM  (C57BL/6 ×  LP.RIII)F1  0  0 
ASII80  bm  ~2  (C57BL/10 ×  129)F~  0  0 
--  C57BL/6  bm  1~  0  0 
AS1074  C57BL/6  (bm  12 ×  LP.RIII)FI  0  0 
AS1097  C57BL/6  (BALB/c ×  bm12)F1  0  0 
* Target cells were that of the donor used for the immunization. 
studies  place the  mutational  site  in  the  IA  subregion.  The serological studies,  per- 
formed both directly and by absorption with H-2 and Ia sera, and using two different 
techniques (cytotoxicity and rosetting) demonstrate very clearly that the bm  12 mutant 
has an extensive alteration in the IA  subregion Ia specificities, but not in H-2K  b (or 
D b) specificities. The initial studies were misleading (Figs. 3 a, b) as they demonstrated 
an alteration  in  the H-2K.33 specificity. However, this antiserum  also contains  the 
Ia.9 specificity and  subsequent  tests revealed  that  H-2.K33  of bm x2 and  C57BL/6 
were  identical,  but  that  the  bm  TM  lacked  the  Ia.9  specificity.  All  other  direct  and 
absorption  studies  with  H-2  antisera  to  private  and  public  H-2  b specificities  also 
demonstrated an identity of C57BL/6  and bm  lz. Although  these findings with  H-2 
antisera  do  not  prove  that  the  mutation  is  in  a  site  other  than  the  H-2K b  locus 
(because serologically detected alterations in H-2.33 in the H-2K b mutants are difficult 
to detect [1, 2]), with the accompanying demonstrable alteration in the IA subregion 
specificities, there is compelling evidence to conclude that the mutation occurred in 
the IA subregion and furthermore, in the Ia-I gene which codes for the Ia specificities 
Ia.3, 8, 9,  15, 20.  All of these specificities appeared to be altered in some way so that 
they are either absent, or have a  reduced amount in bm 12 compared with C57BL/6. 
These specificities are very likely to be on the same molecule, although coprecipitation 
analysis  with  sera  to  all  specificities  has  not  been  simultaneously  performed  to 
conclusively demonstrate this. For example, Ia.8 and 9 have been shown by coprecip- 
itation, to be on the same molecule coded for by the IA subregion (16).  The same was 
shown to be true for specificities Ia.8, 9, and 20 (17).  Specificity Ia.3 was mapped to 
the  IA b  subregion  by  coprecipitation  with  Ia.8  and  9  (17);  and  Ia.15,  originally 
believed  to  be  coded  for  by  the  IE  subregion,  was  mapped  to  the  IA b  subregion 
because  it  also  coprecipitated  with  specificities  Ia.8  and  9  (18).  It  is  therefore 
reasonable to conclude that specificities Ia.3, 8, 9, 15, and 20 are on the same molecule 
coded  for by the  IA b  subregion.  In  bm 12,  the  specificities Ia.8,  9,  15  appear to be 
totally absent and Ia.3 and possibly Ia.20 present in reduced amounts. At this time, 
it  is  not  clear whether  Ia.3,  20  are  indeed  reduced,  or absent,  as  the  sera  to  these 
specificities  are  complex.  It  may  be  that  multiple  specificities  are  present,  some 
decreased or absent in bm 12, e.g., Ia.3, 20, and others not previously detected may be 
present in similar amounts in C57BL/6 and bm ~2. This may explain the high activity 
of the polyspecific A.TH anti-A.TL antiserum, especially by the rosetting technique, McKENZIE,  MORGAN, SANDRIN, MICHAELIDES, MELVOLD,  AND KOHN  1335 
TABLE VI 
MLR Reactions of C57BL/6 and bm t2 
Source of re- 
Experi-  sponder lymph  Source  of stimu-  [aH]Thymidine up-  Stimula- 
ment No.  node cells (1 ×  lator spleen cells  H-2 difference  take  tion index 
106/ml)  (2 ×  106/ml) 
mean cpm  ±  SE 
1  C57BL/6  bm  12  IA (gain)*  44, 830 ± 1,230  25.6 
2  C57BL/6  C57BL/6  --  1,753 :t: 527  -- 
3  bm  12  C57BL/6  IA (loss)~:  17,227 zl: 1,892  18 
4  bm  12  bm  12  --  956 ± 214  -- 
5  C57BL/6  B 10.A(4R)  K  k, IA  k  34,688 + 2,834  19.8 
6  bm  t2  B  10.A(4R)  K  k, IA  k  30,520 :k 2,105  31.9 
7  B  10.A(4R)  C57BL/6  K  b, IA  b  44,978 ± 1.788  36.1 
8  B 10.A(4R)  bm  12  K  b, IA  b*  49,99l ± 4,698  39.3 
9  B10.A(4R)  BI0.A(4R)  --  1,246 ± 236  -- 
* C57BL/6 is presumably responding to the gained specificities  in bm  1~, as is B10.A(4R). 
:~ bm  12, being a loss (as well as a gain) mutation is able to respond to these lost specificities present in 
C57BL/6. 
which could in fact contain the elusive specificities to the thus-far undescribed IE  b 
and IC  b subregions. (The Ia specificities described so far for H-2 b all map in the IA b 
subregion.) Further studies, currently in progress in our laboratory should provide an 
answer to this problem. However, it suffices for this initial serological description of 
the  bm  ~2  mutant  to  categorically state  that  the  mutation has  caused  a  partial  to 
complete  loss  of all  of the  1.,I  b  specificities.  Furthermore, we  have  been unable to 
precipitate an Ia bearing chain with anti-Ia.8 or 9 antisera from the 12~I-radiolabelled 
cell  surface  of the  bm  12  mutant,  in  comparison  with  C57BL/6  (McKenzie et  al. 
Manuscript in preparation.). 
What then of the gain mutation which leads to graft rejection of bm  12 by C57BL/ 
6? We have used several approaches to study this. Firstly, antisera to almost all known 
Ia specificities (Table IV) were tested on C57BL/6 and bm  12. All were nonreactive by 
both  cytotoxicity and rosetting, so  that  alteration to  another known specificity, or 
mutation of the  la-1 b  allele to  another known allele has  not  occurred.  Rather,  the 
mutation  had  led  to  the  appearance  of  a  new  (Ia-I bin)  allele  at  this  locus.  The 
transition from  one  known allele to  another has  not  been  discovered  for  the  11-2 
mutants, but there is recent and conflicting evidence that such changes can occur in 
tumours (19)  and tumour cell variants (19,  20).  The second approach  to detect  the 
gained  specificities  was  standard:  immunizations were  performed  between  bm  12, 
C57BL/6, or Fx hybrids (Table V)  to attempt to produce an anti-bm  lz cytotoxic or 
rosetting antibody. All such attempts have failed thus far but this is the usual finding 
(1)  and we are continuing different approaches to attempt to produce specific anti- 
bm  12  Ia  antibodies. The  immunization in  the  reverse  direction such  as  bm  12  anti- 
C57BL/6 also failed to produce an Ia.8, 9, or any other cytotoxic antibody. Attempts 
to introduce a  different genetic background into these immunization procedures was 
also without effect (Table V) and it should be noted that except for the BALB/c-dm  1 
and drn  e mutations--where there is an alteration or loss of D d +  L d and L d molecules 
respectively, almost all attempts at immunization in mutants have failed to produce 
such an antibody (3). The MLR data (Table V) indicate that in addition to inducing 1336  bm12: AN I  REGION MUTANT 
histocompatibility,  and  serological alterations  in  IA  subregion  specificities,  there  is 
also the induction of surface molecules which stimulate the parental C57BL/6 strain. 
Furthermore,  the  degree of stimulation  is  similar to that  achieved with  differences 
arising of the whole 1-1-2  complex (21-23), or more particularly, with known differences 
in  the IA or K  +  IA regions  (Table VI). At this stage,  it  should  be noted  that  the 
strongest MLR-stimulating determinants are coded for by the Lad-1 locus in the IA 
subregion and other Lad loci are found in K and D regions, in IJ, IC/E, and the non- 
H-2 linked  Mls  locus  (23).  The  finding  that  bm 12  stimulates  C57BL/6  to  respond 
equally well or better than B10.A(4R),  a  difference of the K  +  IA regions, provides 
strong evidence that the mutation has directly effected the Lad-1 locus itself to provide 
new Lad-l-stimulating determinants.  At this  time, the  nature  and number of these 
determinants is unknown as is their relationship to determinants involved in the CML 
phenomenon  but  this  is  currently  under  intensive  study  (K.  Melief,  personal  com- 
munication).  However,  based  on  studies  with  the  H-2K  b mutants,  it  is  likely  that 
multiple specificities are involved (6). 
The bm  TM mutation is of great importance in immunology--far beyond the formal 
description  of  another  mutant.  The  initial  studies  reported  herein,  have  clearly 
answered several important questions. Firstly, are serologically detected Ia specificities 
coded for by the same gene as the histocompatibility H-2IA gene or a closely associated 
H-gene? This question has remained unanswered although a clear association between 
the two was apparent.  Both were products of the same subregion  (IA) and no graft 
rejection occurred when there were no Ia incompatibilities;  furthermore, anti-Ia sera 
could produce skin graft enhancement, and finally, anti-Ia antibodies were produced 
after graft rejection--compelling evidence for the close association, but not necessarily 
identity, of these two different moieties. The finding that the one mutation effected 
both graft rejection and serologically defined specificities indicates that the two are 
most  likely to  be present  on  the  same molecule, and  coded  for by the  same gene; 
although  this  may be an  oversimplification  and  implies  that  T  cells  recognize  the 
same specificities as antibody. 
The second  finding  of importance  is  that  bm 12  stimulates  C57BL/6  in  a  MLR. 
This finding strongly suggests that the Ia determinants defined serologically, and the 
MLR-stimulating determinants, coded for by the Lad-1 locus are present on the same 
molecule, insofar that they are coded for by the same gene (Ia-l). The studies therefore 
point to the identity of the Ia-1, H-2(IA), and Lad-1 genes. We should also question 
the  relevance of the  mutation  in  bm 12 to the definition  of other I  region  products, 
particularly those detected serologically. We have not yet examined/jb but plan to 
do so. What of IE  + and IC  b products? These have not been defined with alloantisera 
in the mouse but we are currently investigating these specificities using both alloan- 
tisera and xenoantisera absorbed with the bm 12 mutant. These studies are of particular 
relevance as it has been suggested that a gene in the IA subregion (possibly Ia-1) also 
codes for one chain in the dimeric IC/IE molecules (24, 25). With appropriate antisera 
and  by using  both  serological  and  biochemical  approaches,  it  may be  possible to 
demonstrate  whether  the  bm  12  mutation  has  also  affected  these  subregions,  either 
directly or indirectly. The bm  TM mutant is therefore clearly of importance and should 
be of further help in determining the relationship of/r genes to Ia specificities, factors 
involved in T-B-cell collaboration, and to other phenomena whose effects map to the 
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Summary 
The B6.C-H-2  b=12 mutant is described and evidence is presented for the mutational 
site  occurring  in  the  IA  subregion.  The  mutant  is  of the  gain  and  loss  type  as 
bm  12  ~  C57BL/6  grafts  are  rejected  in  14-16  d.  Mapping  studies  by  the  gene- 
complementation method using H-2 recombinant strains place the mutation in the K 
or IA regions of the H-2 complex and furthermore,  the use of this test and the use of 
other H-2 mutants indicate that H-2K  b is not the site of the mutation, making the IA 
region the most likely site.  Serological analysis with a  battery of H-2  b, Ia  b, and other 
Ia sera, both by cytotoxicity, rosetting, and also by absorption analysis, indicated  no 
alteration  in  H-2  specifieities,  particularly  in  H-2.K33.  By contrast,  all  of the  Iab 
specificities  coded  for  by  the  IA  subregion  (Ia.3,  8,  9,  15,  and  possibly  20)  are 
extensively altered and are either absent or greatly reduced in amount indicating an 
extensive alteration in the Ia-bearing molecule. The bm 12 mutant strongly stimulates 
the  parental  C57BL/6  strain  in  an  mixed  lymphocyte  reaction  (MLR),  and  the 
reciprocal also occurs, the degree of stimulation  being similar  to that obtained  with 
K  +  IA differences originating in another H-2 haplotype and points to the mutation 
effecting the  Lad-1  locus. The presence of an extensive histocompatibility  change, a 
marked alteration  in the serologically detected Ia specificities, and a strong MLR, all 
produced by the one mutation, provides strong evidence for the identity of the Ia-1, 
Lad-l,  and H-2(IA)  loci in the IA subregion. The bm 12 mutant should be of value in 
determining the relationship of Ia specificities, Ir genes, and other phenomena effected 
by the I region. 
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